Cure CMT and Tamarack Habilitation Team Up for Enhanced Orthotic Solutions for Patients

Cure CMT and Tamarack Habilitation Technologies: A Partnership for Better Mobility

In a significant development for the Charcot-Marie-Tooth (CMT) community, Cure CMT has announced a groundbreaking partnership with Tamarack Habilitation Technologies, a leader in orthotic and prosthetic innovation based in Minnesota. This collaboration represents a remarkable step forward in providing access to essential mobility support for those living with CMT, a condition that affects approximately 1 in 2,500 people globally.

CMT is characterized by progressive muscle weakness and foot drop, leading many individuals to rely on ankle-foot orthoses (AFOs) to enhance their mobility and independence. Recognizing the critical need for effective solutions, Tamarack has made a generous financial contribution to support Cure CMT’s mission while ensuring that its advanced orthotic products are directly accessible to patients via Cure CMT's website.

The founder of Cure CMT, Pat Livney, emphasized the importance of this partnership, stating, "This collaboration signifies a crucial advance in our effort to connect CMT patients with the necessary tools and technology that can enrich their lives. Tamarack's innovative approach to orthotic design perfectly aligns with our mission to elevate the quality of life for individuals affected by CMT."

For over three decades, Tamarack has been at the forefront of developing cutting-edge orthotic solutions. Their proprietary flexure joint technology has transformed AFO design, providing CMT patients with enhanced stability and reduced fatigue, ultimately leading to better outcomes in mobility. Cole Carson, the Owner and CEO of Tamarack, shared his enthusiasm about the partnership: "Our continuous mission has been to improve human performance and comfort. By joining forces with Cure CMT, we can directly reach a community that stands to gain significantly from our advanced orthotic technologies. We are committed to supporting their advocacy and connecting patients to life-changing solutions."

Thanks to this partnership, CMT patients will experience streamlined access to Tamarack’s specialized orthotic components through the Cure CMT website. This innovative approach seeks to eliminate the hurdles that typically obstruct patients from obtaining necessary assistive technologies. Furthermore, Tamarack's financial investment will bolster Cure CMT’s broader educational and research efforts, amplifying its impact within the CMT community.

As research on CMT progresses, the necessity of ensuring that patients have access to the most effective supportive technologies becomes increasingly vital. To maintain their autonomy and enhance their quality of life, individuals with CMT must have the means to acquire essential mobility solutions readily.

Cure CMT is devoted to securing treatments and cures for Charcot-Marie-Tooth disease while offering support to the patients and families affected by this condition. Their initiatives encompass research funding, advocacy, and community engagement, all aimed at hastening advancements toward better health outcomes for the CMT community. For additional details, interested parties can visit cure-cmt.org.

Founded in 1990, Tamarack Habilitation Technologies has continually strived to create innovative orthotic and prosthetic solutions. Their commitment to cutting-edge design and technology has established them as a trusted ally for healthcare providers and patients globally. More information about their offerings can be found at tamarackhti.com.

This partnership not only highlights the importance of innovation and accessibility but also reflects a shared commitment to improving outcomes for individuals facing mobility challenges. With such collaborations, the future of CMT care looks promising, and the CMT community can anticipate more accessible support solutions ahead.